NCT03526679View on ClinicalTrials.gov

Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 12, 2018

Primary Completion Date

June 30, 2021

Study Completion Date

December 30, 2024

Conditions
LeiomyosarcomaLiposarcomaSoft Tissue Sarcoma AdultAdvanced Cancer
Interventions
DRUG

Eribulin

lenvatinib 14mg po daily; eribulin 1.1mg/m2 D1, D8, every 21 days

DRUG

Lenvatinib

lenvatinib 14mg po daily; eribulin 1.1mg/m2 D1, D8, every 21 days

Trial Locations (2)

100

National Taiwan University Hospital, Taipei

Unknown

Taipei Veterans General Hospital, Taipei

All Listed Sponsors
collaborator

Taipei Veterans General Hospital, Taiwan

OTHER_GOV

lead

National Taiwan University Hospital

OTHER

NCT03526679 - Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma | Biotech Hunter | Biotech Hunter